Strategic acquisitions Scantox has a history of expanding capabilities through acquisitions (Gentronix in 2024, QPS Neuro in 2023) and asset acquisitions (TwinStrand Biosciences in 2026), signaling a growth trajectory and growing capabilities in genetic toxicology and nonclinical genomic safety. This suggests opportunities to propose integrated end-to-end nonclinical packages that leverage newly acquired assets.

Expanded CNS capabilities Recent launches include SonoCloud Blood-Brain Barrier disruption technology in 2026, indicating strengthened CNS discovery services. Target neuroscience-focused biotech and pharma programs that require CNS delivery or BBB modulation, offering Scantox as a partner for specialized nonclinical CNS toxicology and pharmacology studies.

DuplexSeq platform Introduction of the Scantox DuplexSeq Mutagenesis App and upgraded bioinformatics platform in 2026 highlights a focus on advanced mutagenesis and genomic safety analytics. Potential upsell to clients needing high-resolution sequencing-based toxicology assessments and custom data analytics.

Global and diversified footprint Headquartered in Denmark with multiple European subsidiaries (UK, Austria, Sweden, Denmark) positions Scantox well for Europe-wide CRO collaborations. Propose multi-site studies to de-risk programs, access local regulatory pathways, and offer synchronized nonclinical timelines for multinational clients.

Accreditations and recognition GLP accreditation for preclinical work, Great Place To Work certification, and industry awards (EcoVadis Bronze Medal, Supplier Recognition Award) reinforce reliability and quality. Leverage these credentials in outreach to risk-conscious pharma and biotech customers seeking compliant, high-quality partner networks.